Literature DB >> 12857966

Genes and genomics of autoimmune inflammation: from Rel to TRAIL.

Youhai H Chen1.   

Abstract

Development of autoimmune diseases requires coordinated expression of a myriad of genes. To explore the spectrum and global patterns of gene expression during autoimmune inflammation, we have recently performed functional genomic studies of autoimmune inflammation in the central nervous system (CNS). Inflammation in the CNS not only induced the expression of many immune-related genes, but also significantly altered the gene expression profile of neural cells. A number of unique clusters of genes were identified, which represent putative immune and nervous responses in autoimmune inflammation. This review will focus on two clusters of genes that we have been studying during the past few years: the Rel/nuclear factor (NF)-kappaB family and the tumor necrosis factor (TNF) family.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857966     DOI: 10.1385/IR:27:2-3:169

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  96 in total

1.  Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines.

Authors:  M Arsura; M J FitzGerald; N Fausto; G E Sonenshein
Journal:  Cell Growth Differ       Date:  1997-10

2.  Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity.

Authors:  C Muñoz; D Pascual-Salcedo; M C Castellanos; A Alfranca; J Aragonés; A Vara; J M Redondo; M O de Landázuri
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

3.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.

Authors:  M S Sheikh; Y Huang; E A Fernandez-Salas; W S El-Deiry; H Friess; S Amundson; J Yin; S J Meltzer; N J Holbrook; A J Fornace
Journal:  Oncogene       Date:  1999-07-15       Impact factor: 9.867

Review 4.  Signalling by CD95 and TNF receptors: not only life and death.

Authors:  C Magnusson; D L Vaux
Journal:  Immunol Cell Biol       Date:  1999-02       Impact factor: 5.126

5.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor.

Authors:  S Gerondakis; A Strasser; D Metcalf; G Grigoriadis; J Y Scheerlinck; R J Grumont
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

8.  Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.

Authors:  N Itoh; A Imagawa; T Hanafusa; M Waguri; K Yamamoto; H Iwahashi; M Moriwaki; H Nakajima; J Miyagawa; M Namba; S Makino; S Nagata; N Kono; Y Matsuzawa
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

10.  NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses.

Authors:  T S Doi; T Takahashi; O Taguchi; T Azuma; Y Obata
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.